See more : Kushim, Inc. (2345.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bolt Biotherapeutics, Inc. (BOLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bolt Biotherapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xinyu Iron & Steel Co., Ltd (600782.SS) Income Statement Analysis – Financial Results
- Tensho Electric Industries Co., Ltd. (6776.T) Income Statement Analysis – Financial Results
- Veolia Environnement S.A. (VVD.DE) Income Statement Analysis – Financial Results
- PT Charoen Pokphand Indonesia Tbk (PPOKF) Income Statement Analysis – Financial Results
- Berry Global Group, Inc. (0HN1.L) Income Statement Analysis – Financial Results
Bolt Biotherapeutics, Inc. (BOLT)
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages. It is also developing programmed cell death-ligand 1 program for tumors that are nonresponsive to immune checkpoint blockade. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood city, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 7.88M | 5.73M | 1.26M | 231.00K | 215.00K | 0.00 |
| Cost of Revenue | 1.88M | 4.89M | 3.67M | 40.36M | 26.00M | 302.00K |
| Gross Profit | 5.99M | 838.00K | -2.41M | -40.13M | -25.79M | -302.00K |
| Gross Profit Ratio | 76.08% | 14.63% | -191.43% | -17,370.56% | -11,993.95% | 0.00% |
| Research & Development | 61.54M | 73.12M | 75.66M | 40.36M | 26.00M | 9.42M |
| General & Administrative | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 22.53M | 22.93M | 18.39M | 9.06M | 5.18M | 2.21M |
| Other Expenses | 0.00 | 0.00 | -6.08M | -11.75M | -42.00K | -153.00K |
| Operating Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Cost & Expenses | 84.07M | 96.05M | 94.05M | 49.41M | 31.18M | 11.63M |
| Interest Income | 7.00M | 2.22M | 281.00K | 199.00K | 524.00K | 193.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.85M | 4.89M | 3.67M | 2.50M | 1.33M | 302.00K |
| EBITDA | -74.34M | -88.66M | -91.60M | -48.57M | -30.63M | -11.33M |
| EBITDA Ratio | -943.91% | -1,547.48% | -6,786.59% | -15,941.99% | -14,228.84% | 0.00% |
| Operating Income | -76.20M | -90.32M | -92.79M | -49.18M | -30.97M | -11.63M |
| Operating Income Ratio | -967.45% | -1,576.56% | -7,364.13% | -21,290.91% | -14,404.19% | 0.00% |
| Total Other Income/Expenses | 7.00M | 2.22M | -5.80M | -11.55M | 482.00K | 40.00K |
| Income Before Tax | -69.20M | -88.10M | -98.59M | -60.73M | -30.49M | -11.59M |
| Income Before Tax Ratio | -878.58% | -1,537.76% | -7,824.68% | -26,289.18% | -14,180.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.22M | 5.80M | 11.55M | -482.00K | 40.00K |
| Net Income | -69.20M | -85.88M | -104.39M | -72.27M | -30.01M | -11.59M |
| Net Income Ratio | -878.58% | -1,498.95% | -8,285.24% | -31,287.45% | -13,955.81% | 0.00% |
| EPS | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| EPS Diluted | -1.83 | -2.30 | -2.79 | -1.99 | -0.85 | -1.23 |
| Weighted Avg Shares Out | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
| Weighted Avg Shares Out (Dil) | 37.81M | 37.36M | 37.40M | 36.25M | 35.10M | 9.42M |
BOLT Deadline: Rosen Law Firm Urges Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14,...
Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions
LOS ANGELES, CA / ACCESSWIRE / September 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b)...
BOLT Investors Have the Opportunity to Lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Sept. 02, 2024 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. (“Bolt” or “the Company”) (NASDAQ: BOLT) for violations of §§10(b) and...
IMMINENT BOLT DEADLINE to Actively Participate in the Class Action Lawsuit for Bolt Biotherapeutics, Inc.: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Last Few Hours!
NEW YORK CITY, NY / ACCESSWIRE / September 2, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT)...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bolt Biotherapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – BOLT
NEW YORK, NY / ACCESSWIRE / September 1, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or the "Company") (NASDAQ:BOLT) and certain officers. The class action, filed in the United...
A Securities Fraud Lawsuit Has Been Filed On Behalf Of Investors In Bolt Biotherapeutics Inc And The Schall Law Firm Wants Affected Investors To Reach Out
LOS ANGELES, CA / ACCESSWIRE / September 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b)...
BOLT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Bolt Biotherapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK CITY, NY / ACCESSWIRE / September 1, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT)...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Bolt To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $50,000 in Bolt between February 5, 2021 and...
Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bolt Biotherapeutics, Inc. ("Bolt" or "the Company") (NASDAQ:BOLT) for violations of 10(b)...
BOLT Deadline: BOLT Investors Have Opportunity to lead Bolt Biotherapeutics, Inc. Securities Fraud Lawsuit
NEW YORK , Aug. 30, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Bolt Biotherapeutics, Inc. (NASDAQ: BOLT) between February 5, 2021 and May 14, 2024, both dates inclusive (the "Class...
Source: https://incomestatements.info
Category: Stock Reports